



September 8, 2023

Company name: PeptiDream Inc.
Representative: Patrick C. Reid, President and CEO
(Securities code: 4587; TSE Prime Market)
Inquiries: Yuko Okimoto, Head of Investor Relations
(Tel: +81-44-223-6612)

Payment of contingent consideration for the acquisition of the radiopharmaceutical business

PeptiDream Inc. (President and CEO: Patrick C. Reid, Headquarters: Kawasaki City, Kanagawa Prefecture, hereinafter “Company”) today announced that with the approval of a partial change to the indication of AMYViD[®], an amyloid PET imaging agent, received by PDRadiopharma Inc., a consolidated subsidiary of the Company, at the end of August 2023, and the new indication for "visualization of beta amyloid plaques in the brain of patients with mild cognitive impairment or suspected to have dementia due to Alzheimer's disease", a contingent payment of 4 billion yen to Fujifilm Corporation has been incurred.

No further payments will be made in the future in connection with the acquisition of the radiopharmaceutical business. The payment is planned to be funded by cash on hand and long-term borrowings from financial institutions.

On September 2, 2021, the Company announced the acquisition of the radiopharmaceutical business (please refer to our announcement, "PeptiDream Announces Agreement to Acquire FUJIFILM Toyama Chemical's Radiopharmaceutical Business from Fujifilm"). In addition to the acquisition consideration of 22,059 million yen, the share purchase agreement with Fujifilm Corporation also includes a contingent consideration of 4 billion yen to be incurred if expansion of the indication for mild cognitive impairment (MCI) of AMYViD[®] was approved in Japan by the end of April 2024. The payment of the contingent consideration has been incurred after confirming that the condition has been achieved. Of the contingent consideration of 4 billion yen, 50% has already been recorded in the year ending December 31, 2022, and the remaining 50% is expected to be recorded as financial expenses in the year ending December 31, 2023.

This payment has been factored in our consolidated financial forecasts for the fiscal

year ending December 31, 2023, which was announced on February 14, 2023 and there are no changes to our forecast.